Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic target for managing metabolic syndromes. These Trulicity manufacturer naturally occurring substances are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 agents possess promising therapeutic results i